Dr. Ferozuddin Feroz,
The Minister of Public Health
Ministry of Public Health
Great Masoud Road
Kabul
Afghanistan

7 June 2016

Decision Letter: Revision of Gavi-funded 2016 doses for Pneumococcal Vaccine

Dear Minister,

I am writing in relation to Afghanistan’s request for renewal of Pneumococcal Vaccine support which was approved by Gavi in July 2015 and communicated to the country through the Decision Letter dated 15 September 2015.

Following the country request for additional doses, we have revised the volumes of the Gavi-supported portion and related injection safety materials for the year 2016. The previous approval for 2016 was for a total of 4,383,000 doses equivalent to US$22,033,000. The revised approval is for 5,243,400 doses equivalent to US$26,269,000. Kindly notice Afghanistan’s co-financing portion remains the same.

The attached Appendix A, replaces the Appendix A-2 provided to the Country on the 15 September 2015 Decision Letter, and provides the financial and programmatic information for this approval.

Please do not hesitate to contact my colleague Ms. Anne Cronin, at «acronin@gavi.org» if you have any questions or concerns.

Yours sincerely,

Hind Khatib-Othman
Managing Director, Country Programmes

cc: The Minister of Finance
Director Planning Unit, MoH
The EPI Manager
WHO Country Representative
UNICEF Country Representative
Regional Working Group
UNICEF Programme Division
UNICEF Supply Division
## Afghanistan Vaccine Support

This Decision Letter sets out the Programme Terms of a Programme.

1. **Country:** Afghanistan
2. **Grant Number:** 1315-AFG-12c-X / 1619-AFG-12c-X
3. **Date of Decision Letter:** 07/06/2016
4. **Date of the Partnership Framework Agreement:** 30/04/2013
5. **Programme Title:** NVS, Pneumococcal Routine
6. **Vaccine type:** Pneumococcal
7. **Requested product presentation and formulation of vaccine:** Pneumococcal (PCV13), 1 dose(s) per vial, LIQUID
8. **Programme Duration**: 2013 - 2016
9. **Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):**

<table>
<thead>
<tr>
<th>Programme Budget (US$)</th>
<th>2013-2015</th>
<th>2016</th>
<th>Total²</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>US$43,987,394³</td>
<td>US$26,269,000</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>US$70,256,394</td>
</tr>
</tbody>
</table>

10. **Vaccine Introduction Grant:** Not applicable

11. **Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):**

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Gavi funds in each year</th>
<th>2013-2015</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Pneumococcal vaccines doses</td>
<td>5,243,400</td>
<td></td>
</tr>
<tr>
<td>Number of AD syringes</td>
<td>5,839,100</td>
<td></td>
</tr>
<tr>
<td>Number of re-constitution syringes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of safety boxes</td>
<td>64,250</td>
<td></td>
</tr>
<tr>
<td><strong>Annual Amounts (US$)</strong></td>
<td>US$43,987,394⁴</td>
<td>US$26,269,000</td>
</tr>
</tbody>
</table>

12. **Procurement agency:** UNICEF. The Country shall release its Co-Financing payments each year to UNICEF.

13. **Self-procurement:** Not applicable.

---

¹ This is the entire duration of the programme.
² This is the total amount endorsed by Gavi for the entire duration of the programme. This should be equal to the total of all sums in the table.
³ This is the consolidated amount for all previous years.
⁴ This is the consolidated amount for all previously approved years.
14. **Co-financing obligations**: Reference code: 1619-AFG-12c-X-C

According to the Co-Financing Policy, the Country falls within the group of Initial self-financing phase (formerly referred to as low-income).

The following table summarises the Co-Financing Payment and quantity of supply that will be procured with such funds in the relevant year.

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Country funds in each year</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of vaccine doses</td>
<td>311,400</td>
</tr>
<tr>
<td>Number of AD syringes</td>
<td></td>
</tr>
<tr>
<td>Number of re-constitution syringes</td>
<td></td>
</tr>
<tr>
<td>Number of safety boxes</td>
<td></td>
</tr>
<tr>
<td>Value of vaccine doses (US$)</td>
<td>US$1,045,323</td>
</tr>
<tr>
<td><strong>Total Co-Financing Payments (US$)</strong> (including freight)</td>
<td>US$1,109,500</td>
</tr>
</tbody>
</table>

15. **Operational support for campaigns**: Not applicable

16. **Additional documents to be delivered for future disbursements**:

<table>
<thead>
<tr>
<th>Reports, documents and other deliverables</th>
<th>Due dates</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Annual Progress Report or equivalent</strong></td>
<td>To be agreed with Gavi Secretariat in the context of GAMR Internal Appraisal for Support 2016</td>
</tr>
</tbody>
</table>

17. **Financial Clarifications**: Not applicable.

18. **Other conditions**:

Please confirm whether vaccines and equipment financed by GAVI are insured as indicated by the provisions of the Partnership Framework Agreement signed between the Government of Afghanistan and Gavi.

Signed by,

**On behalf of Gavi**

Hind Khatib-Othman

Managing Director, Country Programmes

7 June 2016